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A B S T R A C T
Background. Cardiac surgery is a leading cause of acute kidney
injury (AKI). Such AKI patients may develop progressive
chronic kidney disease (CKD). Others, who appear to have sus-
tained no permanent loss of function (normal serum creati-
nine), may still lose renal functional reserve (RFR).
Methods. We extended the follow-up in the observational
‘Preoperative RFR Predicts Risk of AKI after Cardiac Surgery’
study from hospital discharge to 3 months after surgery for 86
(78.2%) patients with normal baseline estimated glomerular fil-
tration rate (eGFR), and re-measured RFR with a high oral pro-
tein load. The primary study endpoint was change in RFR.
Study registration at clinicaltrials.gov Identifier: NCT03092947,
ISRCTN Registry: ISRCTN16109759.
Results. At 3 months, three patients developed new CKD. All
remaining patients continued to have a normal eGFR (93.3 6
15.1 mL/min/1.73 m2). However, when stratified by post-
operative AKI and cell cycle arrest (CCA) biomarkers, AKI
patients displayed a significant decrease in RFR {from 14.4
[interquartile range (IQR) 9.5 24.3] to 9.1 (IQR 7.1 12.5)
mL/min/1.73 m2; P< 0.001} and patients without AKI but with
positive post-operative CCA biomarkers also experienced a
similar decrease of RFR [from 26.7 (IQR 22.9 31.5) to 19.7
(IQR 15.8 22.8) mL/min/1.73 m2; P< 0.001]. In contrast,
patients with neither clinical AKI nor positive biomarkers had
no such decrease of RFR. Finally, of the three patients who de-
veloped new CKD, two sustained AKI and one had positive
CCA biomarkers but without AKI.
Conclusions. Among elective cardiac surgery patients, AKI or
elevated post-operative CCA biomarkers were associated with
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decreased RFR at 3 months despite normalization of serum cre-
atinine. Larger prospective studies to validate the use of RFR to
assess renal recovery in combination with biochemical bio-
markers are warranted.
Keywords: cell cycle arrest biomarkers, chronic kidney dis-
ease, kidney stress test, protein load, renal recovery
I N T R O D U C T I O N
Each year, more than 2 million cardiac operations are per-
formed worldwide [1]. Acute kidney injury (AKI) is a common
complication of cardiac surgery [2, 3], and predicts adverse
short- and long-term outcomes regardless of other risk factors
[4, 5]. Despite abundant data on the prognostic importance of
AKI, there is limited information available on renal recovery af-
ter cardiac surgery. Although identification of patients at risk
for incomplete recovery has important implications for long-
term management, to date, no reliable method exists to assess
renal recovery outside of measurement of serum creatinine.
Sustained loss of glomerular filtration rate (GFR) is common
following cardiac surgery, with 25% of patients exhibiting a loss
of at least 10mL/min/1.73 m2 by 1 year [6]. This occurs even in
patients without AKI, suggesting that kidney injury occurs
without overt changes in function as traditionally measured by
serum creatinine [6]. However, GFR is a dynamic parameter,
which is diet-dependent and is not maximal in the ‘unstressed’
(resting) condition [7]. Conversely, an apparently normal rest-
ing GFR can result from glomerular hyperfiltration of remain-
ing nephrons, and may be incorrectly interpreted to
indicate normal renal function and be deleterious in the long
run [8–10].
The concept of renal functional reserve (RFR) describes the
capacity of the kidneys to increase GFR in response to stimuli
(e.g. protein load) and is defined by the difference between peak
‘stress’ GFR and the resting GFR [7, 9]. Recently, the assessment
of RFR has been standardized [11]. RFR might be utilized to
better categorize patients after an episode of AKI [7, 9]. Thus, in
patients with apparently normal post-surgery GFR as measured
by serum creatinine, there may be a subgroup with impaired
RFR and at heightened risk for CKD and other episodes of AKI.
Novel urinary biomarkers [tissue inhibitor metalloproteinases-
2 (TIMP-2) and insulin-like growth factor-binding protein 7
(IGFBP7)] have been identified as more sensitive for the detection
of kidney injury or stress than serum creatinine [12]. Because of
their likely biological effects, they are referred to as cell cycle arrest
(CCA) biomarkers. Such CCA biomarkers may also assist in the
identification of patients at risk of subsequent decrease of RFR. In
this case, patients may have ‘sub-clinical’ levels of peri-operative
injury as defined by serum creatinine yet have suffered injury sig-
nificant enough to lead to decrease of RFR [13].
We recently reported on the use of RFR and CCA bio-
markers to predict AKI in a series of 110 patients without un-
derlying chronic kidney disease (CKD) undergoing elective
cardiac surgery [10]. In this pre-planned subgroup analysis of
that study, we sought to determine whether the occurrence of
AKI [as defined by Kidney Disease: Improving Global
Outcomes (KDIGO) criteria [14]] affects RFR 3 months after
surgery even in patients without changes (pre- and post-
surgery) in estimated GFR (eGFR); and whether urinary
[TIMP-2]•[IGFBP7] levels predict such change in RFR.
M A T E R I A L S A N D M E T H O D S
Study design and participants
The ‘Preoperative RFR Predicts Risk of AKI after Cardiac
Surgery’ study has been described in detail elsewhere [10].
Briefly, 110 adult patients without pre-existing CKD [eGFR
60 mL/min/1.73 m2 (CKD-Epidemiology Collaboration equa-
tion [15])] undergoing elective cardiac surgery with cardiopul-
monary bypass (coronary artery bypass, valve replacements,
combined or other surgery) were enrolled between November
2014 and October 2015 at the Department of Cardiac Surgery
of San Bortolo Hospital, Vicenza, Italy. Pre-operative RFR was
measured using a high oral protein load test 1 day prior to sur-
gery, and serial post-operative urine samples were analysed for
[TIMP-2]•[IGFBP7]. The study was approved by the local
Human Research Ethics Committee, and was conducted
according to the principles of the Declaration of Helsinki. All
patients provided written informed consent. The study is regis-
tered at clinicaltrials.gov (Identifier: NCT03092947) and the
ISRCTN Registry (ISRCTN16109759).
All patients included in the ‘Preoperative RFR Predicts Risk
of AKI after Cardiac Surgery’ study were re-contacted 3 months
after surgery to determine their willingness to repeat the kidney
stress test (see Supplementary data, Methods section). A total of
86 patients (78.2%) completed the 3 months’ follow-up per pro-
tocol until March 2016 at the Nephrology Department of San
Bortolo Hospital, and were considered for subgroup analysis.
RFR assessment
RFR was assessed using a previously described protocol (kid-
ney stress test) with oral protein load (see Supplementary data
for complete description) [7, 10, 11, 16–18]. Both resting GFR
and post-protein load (‘stress’) GFR were calculated using en-
dogenous creatinine clearance, and were corrected for body sur-
face area using the Dubois method [7, 10, 11, 16–18]. Urine
collection was done by supervised voiding and confirmed for
completeness by bladder scanning.
Resting and stress GFR were measured pre-operatively and
3 months after the surgery. The difference between the highest
‘stress’ GFR and resting GFR was defined as the RFR. Preserved
RFR 3 months after surgery was defined as RFR equal to or
greater than pre-operative values.
Laboratory methods are presented in the Supplementary
data. All values for [TIMP-2]•[IGFBP7] are reported in units of
(ng/mL)2/1000. In accordance with the validation study [12],
the cut-off of [TIMP-2]•[IGFBP7]>0.3 was used for predicting
changes in RFR. Overall, the level of completeness of collected
data was 100%.
Endpoints
The primary endpoint was changes in RFR 3 months after
surgery. Secondary endpoints included (i) percentage of
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patients with normal or unmodified eGFR, but reduced RFR at
3 months and (ii) association of pre-operative RFR and post-
operative urinary biomarker levels with reduced RFR at
3 months. We also sought to determine the risk factors associ-
ated with a reduced RFR at 3 months. AKI and CKD were de-
termined by using full KDIGO criteria [14, 19], and were
diagnosed and staged by an adjudication committee of three ex-
pert nephrologists who were blinded to the results of RFR test-
ing and biomarker results. Serum creatinine levels were taken at
hospital admission (before protein loading) and immediately
before surgery to detect possible changes due to creatinine con-
tent of red meat used as protein load. Positive fluid balance and
haemodilution were considered by the adjudicators in diagnos-
ing and staging AKI when appropriate [20]. Reversal of AKI
was defined as the absence of any stage of AKI by either serum
creatinine or urine output criteria [21]. Clinical variables were
abstracted from patient medical records. Use of renal replace-
ment therapy was at the discretion of the attending physician.
Peri-operative myocardial infarction and stroke were defined as
previously described [22]. All potentially nephrotoxic drugs
(non-steroidal anti-inflammatory drugs, aminoglycosides, van-
comycin and intravenous contrast media) were recorded during
the study period.
Statistical analysis
Estimates of the potential effect and variance of protein in-
take were taken from previous publications [23, 24]. Shapiro–
Wilk’s and Levene’s tests were used to test Gaussian distribu-
tion and homoscedasticity of continuous variables, respectively.
Student’s t-test or one-way analysis of variance, Mann–
Whitney U test, Kruskal–Wallis one-way analysis test, Pearson
or McNemar’s chi-squared test (categorical variables) were
used to evaluate the difference between non-AKI and AKI
groups or between with patients with or without decrease in
RFR. Two-sided P-values <0.05 were considered statistically
significant. Data are presented as mean 6 SD or median [inter-
quartile range (IQR)], or as n (%).
Linear regression was used to describe the relationship be-
tween RFR at 3 months (dependent variable) and other predic-
tor variables (independent variables). A receiver operating
characteristic (ROC) curve was created for RFR at 3 months.
Using the Liu method, we determined an optimal cut-off and
analysed its sensitivity and specificity as well as the relative risk
of decreased RFR. STATA version 13.1 software (Stata
Corporation, College Station, TX, USA) was used for all
analyses.
R E S U L T S
Patients and treatments
Of the 110 patients enrolled in the ‘Preoperative RFR
Predicts Risk of AKI After Cardiac Surgery’ study, 86 were
available for follow-up (Figure 1). Among those who were lost
to follow-up, one patient was readmitted to hospital due to
post-operative complications and died of multiple organ failure.
Baseline characteristics and renal function measures and bio-
markers are shown in Tables 1 and 2, respectively. Additional
baseline characteristics, process of care and outcomes variable-
sand biomarker characteristics are shown in Supplementary
data, Tables S1–S3. Average resting (measured by creatinine
clearance) and eGFR were 102.7 6 14.7 and 89.5 6 14.6 mL/
min/1.73 m2, respectively.
AKI rates and test performance
Of 86 patients in the analysis, 10 (11.6%) developed AKI
according to creatinine criteria, and none met urine output cri-
teria. Of these, seven (8.1%) had Stage 1 AKI, and three (3.5%)
had severe AKI (Stage 2, two patients; Stage 3, one patient). All
10 patients experienced only one distinct episode of AKI
throughout the hospital stay and all had urinary [TIMP-
2]•[IGFBP7]>0.3 within 12 h after surgery. Immediate pre-op-
erative serum creatinine levels did not differ from creatinine
levels prior to protein loading (Table 2).
Renal recovery
At hospital discharge, all patients had normal renal function
as defined by a normal eGFR (60 mL/min/1.73 m2), including
the 10 patients who developed AKI (complete reversal)
(Figure 2; for comprehensive description see Supplementary
data, Figure S2).
At 3 months, measured resting GFR remained normal in all
patients (60 mL/min/1.73 m2, apparent full recovery), with an
average of 96.4 6 15.3 mL/min/1.73 m2. Mean eGFR was also
91.3 6 16.2 mL/min/1.73 m2. However, three patients fulfilled
the eGFR criteria for new CKD—two had post-operative AKI.
These patients were categorized as KDIGO [19] Stage G3aA1
(eGFR 57 mL/min/1.73 m2, resting GFR 69.4 mL/min/1.73 m2)
and G3aA2 (eGFR 58 mL/min/1.73 m2, resting GFR 64 mL/min/
1.73 m2). The remaining patient with evidence of new CKD was
categorized as Stage G3aA1 (eGFR 59 mL/min/1.73 m2, resting
GFR 65 mL/min/1.73 m2). This patient did not develop post-op-
erative AKI but did have elevated urine levels [TIMP-
2]•[IGFBP7] (0.35) post-operatively. Overall, the new CKD
patients showed a decrease in eGFR from 63.0 (IQR 61.366.0)
to 52.5 (IQR 46.059.0) mL/min/1.73 m2, respectively.
Three-month RFR
Three months after surgery, the 83 (96.5%) remaining
patients without new onset CKD showed a median decrease in
RFR from 25.7 (IQR 20.531.4) to 22.3 (IQR 15.627.1) mL/
min/1.73 m2 (P< 0.001), even though eGFR remained
unchanged from 94.5 (88.0102.5) to 93.5 (84.0102.0)
(P¼ 0.8). The eight AKI patients who did not develop CKD ex-
perienced a decrease in RFR, with a median decrease of 4.7
(IQR 10.7 to 2.41) mL/min/1.73 m2 [RFR fell from 14.4
(IQR 9.524.3) to 9.1 (IQR 7.112.5) mL/min/1.73 m2,
P< 0.001; Figure 3A]. The mean average percent decrease in
RFR was 36.9 6 14.4% (P< 0.001). In contrast, median eGFR
again remained unchanged from 85.5 (IQR 76.097.0) to 84.5
(IQR 67.095.0) mL/min/1.73 m2 (P¼ 0.5).
When sub-grouped by stage, patients with AKI Stage 1 had a
median decrease in RFR of 2.6 mL/min/1.73 m2 (IQR 6.3 to
2.3;30.1 6 11.2%), and those with severe AKI (Stages 23)
had a median decrease in RFR of 16.2 mL/min/1.73 m2
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(IQR 16.5 to 3.6; 52.9 6 3.6%; P< 0.001; Figure 3B).
eGFR again remained unchanged both in Stage 1 and Stages
23 patients (Supplementary data, Table S4).
Of the 32 non-CKD patients who were AKI-negative but
biomarker-positive, only 1 patient (3.0%) showed a RFR equal
to pre-operative values (P< 0.001). AKI-negative but bio-
marker-positive patients also had a significant median decrease
in RFR [6.6 mL/min/1.73 m2 (IQR 10.3 to 4.9) from 26.7
(IQR 22.931.5) to 19.7 (IQR 15.822.8) mL/min/1.73 m2;
P< 0.001; Figure 3C], a decrease of 27.5 6 12.7% compared
with pre-operative values (P< 0.001). eGFR remained
unchanged (Supplementary data, Table S4). When compared
with the AKI-positive group, all AKI-negative and biomarker-
positive patients had a median decrease in RFR >4.7 mL/min/
1.73 m2 (P< 0.001).
In contrast, of the 43 patients who were AKI-negative and
biomarker-negative, 17 (39.5%) had RFR equal to or greater
than pre-operative values (P< 0.001) and none developed
CKD. In these patients, RFR was preserved [median change was
0.8 mL/min/1.73 m2 (IQR1.6 to 1.1)]. The magnitude of de-
crease in RFR at 3 months was 0.04 6 4.0%, which was signifi-
cantly different from biomarker positive or AKI (creatinine)-
positive patients (P< 0.001). Among the 43 AKI-negative
and biomarker-negative patients, none had a decrease in
RFR >4.7 mL/min/1.73 m2 when compared with AKI-
positive patients (P< 0.001). eGFR remained unchanged
(Supplementary data, Table S4).
When we compared CCA biomarkers levels in non-CKD
patients who displayed a decrease in RFR at 3 months compared
with those who did not, independent of AKI occurrence, CCA
FIGURE 1: Study flow chart and outcomes. The flowchart of the ‘Preoperative RFR Predicts Risk of AKI after Cardiac Surgery’ study shows
that 110 patients were included in the initial study and 24 patients were lost to follow-up for the follow-up analysis. For bioimpedance proce-
dure, see Supplemental Methods.
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biomarkers levels at 30 min after cardiopulmonary bypass
(P¼ 0.007) and peak CCA biomarker values within 12 h after
surgery (P¼ 0.001) were significantly greater in patients with a
decrease in RFR (Table 3). Among different time points, the
ROC curve of peak CCA biomarker values within 12 h after sur-
gery was significantly more accurate (area under the receiver
operating characteristics curve, AUC¼ 0.75) to identify patients
who developed a decrease in RFR, with an estimated cut-off
point of 0.3 (sensitivity 0.68 and specificity 0.78; Table 4).
In addition, we found significant decreases between pre-op-
erative and follow-up RFR values in non-CKD patients with
positive post-operative biomarker values [[TIMP-2]•[IGFBP7]
>0.3: 25.9 (IQR 19.4–31.1) to 17.0 (IQR 12.522.5) versus
0.3: 25.8 (IQR 19.4–22.72) to 26.0 (IQR 20.431.7) mL/min/
1.73 m2, P< 0.001; Figure 4]. The absolute decrease in median
RFR was significantly greater in magnitude in patients who
displayed a positivity for biomarkers within 12 h after
surgery [>0.3: 6.3 (IQR 10.7 to 4.6) mL/min/1.73 m2;
30.0 6 13.6% versus 0.3: 0.88 (IQR 2.0 to 1.1) mL/min/
1.73 m2;0.3 6 13.4%; P< 0.001].
Patients with CCA biomarker values >0.3 within 12 h after
surgery were 1.6-fold likely to experience a decrease in RFR at
3 months (95% confidence interval 1.25–2.02; P< 0.001). RFR
values at 3 months were associated with pre-operative RFR, age
and peak CCA biomarkers values within 12 h after surgery
(Supplementary data, Table S5). Peri-operative variables
(e.g. cardiopulmonary bypass time and aortic clamp time),
however, did not show a significant association with RFR
at 3 months.
D I S C U S S I O N
Key findings
In patients with a normal eGFR before, and 3 months after,
elective cardiac surgery, we found that median RFR decreased
in patients who developed peri-operative AKI. In patients
Table 1. Baseline characteristicsa
All patients No AKI AKI Stage 1 AKI Stages 23
(n¼ 86) (n¼ 76) (n¼ 7) (n¼ 3)
Demographics
Age (years) 60.7 (51.567.7) 59.9 (51.466.4) 72.5 (60.677.5) 49.9 (47.775.6)
Gender, male 63 (73.3) 56 (73.7) 5 (71.4) 2 (66.7)
Body mass index (kg/m2) 25.9 6 3.5 25.4 6 3.4 28.9 6 3.0 30.2 6 2.4
Comorbidities
Hypertension 55 (63.9) 47 (61.8) 6 (85.7) 2 (66.6)
Diabetes mellitus Type 2 5 (5.8) 4 (5.3) 1 (14.3) 0 (0)
Peripheral vasculopathy 5 (5.8) 3 (3.9) 1 (14.3) 1 (33.3)
Previous heart surgery 5 (5.8) 4 (5.3) 1 (14.3) 0 (0)
Left ventricular ejection fraction (%) 61.5 (58.067.0) 61.5 (57.566.0) 59.0 (55.069.0) 70.0 (65.071.0)
Medication
Beta-blocker 29 (33.7) 23 (30.3) 3 (42.9) 3 (100)
ACE inhibitor or angiotensin II receptor blocker 40 (46.5) 33 (43.2) 5 (71.4) 2 (66.7)
Statin 30 (34.9) 26 (34.2) 2 (28.6) 2 (66.7)
Diuretic 18 (20.9) 15 (19.7) 3 (42.9) 0 (0)
Aldosterone antagonist 3 (3.5) 3 (3.9) 0 (0) 0 (0)
Baseline clinical data
Leucocytes (109/L) 6.4 6 1.9 6.4 6 1.9 6.0 6 0.9 7.7 6 1.1
Haemoglobin (g/dL) 14.0 6 1.3 14.1 6 1.2 13.9 6 0.9 12.7 6 2.6
Platelets (109/L) 214.1 6 47.7 212.5 6 44.0 189.0 6 39.3 313.7 648.3
Albumin (g/dL) 3.9 6 0.2 3.9 6 0.3 3.9 6 0.2 3.9 6 0.1
NYHA classification
1 37 (43.0) 36 (47.4) 1 (14.3) 0 (0)
2 49 (57.0) 40 (52.6) 6 (85.7) 3 (100)
3 0 (0) 0 (0) 0 (0) 0 (0)
EuroSCORE II for operative risk (%)b 1.0 (0.71.6) 1.0 (0.71.6) 1.5 (1.04.3) 0.7 (0.611.8)
Surgical clinical data
Aortic cross-clamp time (min) 85.3 6 31.7 82.9 6 29.8 90 6 39.8 136.0 6 21.3
Cardiopulmonary bypass time (min) 116 (150.0177.0) 111.5 (97.0144.5) 153.0 (105.0192.0) 282.0 (166.0–301.0)
Procedure
Coronary artery bypass graft only 2 (2.33) 2 (2.6) 1 (10) 0 (0)
Valve only 46 (53.5) 42 (55.3) 3 (42.9) 1 (33.3)
Combined or other 38 (44.2) 32 (42.1) 4 (57.1) 2 (66.7)
ICU clinical data
ICU stay (h) 51.0 (41.072.0) 45 (41.066.0) 55.5 (40.088.0) 106.0 (85.0189.0)
Hospital stay (days) 5.5 6 2.4 5.2 6 1.7 5.5 6 2.0 6 6 0
Values are mean 6 SD, n (%) or median [25th–75th percentile (interquartile range)]. Categorical variables are expressed as n (%).
aAdditional data are provided in the Supplementary data, Tables S1 and S2. There were no significant differences between the groups except for beta-blocker (P¼ 0.04), aortic cross-
clamp time (P¼ 0.04), cardiopulmonary bypass time (P¼ 0.004), ICU stay (P¼ 0.01) and hospital stay (P¼ 0.002).
bThe European System for Cardiac Operative Risk Evaluation (EuroSCORE) is calculated by means of a logistic-regression equation and ranges from 0% to 100%, with higher scores
indicating greater risk.
ACE, angiotensin-converting enzyme; NYHA, New York Heart Association.
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without AKI, but with increased urinary CCA biomarker levels,
median RFR also fell. Conversely, for patients without AKI and
with no change in biomarkers, median RFR at 3 months
remained presevered, and no patient experienced a decrease in
RFR>4.7 mL/min/1.73 m2.
Relationship with previous studies
Although RFR declines with age, resting GFR values remain
within the normal range [23, 24]. This is in accordance with sig-
nificant nephron loss in healthy human kidneys with ageing
[8]. A reduction of RFR compared with young healthy volun-
teers [11, 16] has also been observed in physiological (preg-
nancy [17] and elderly persons [23]) and pathological
conditions (CKD [9], chronic obstructive pulmonary disease
[25], solitary kidney [18] and diabetes [26]). To date, however,
no study has evaluated whether AKI or increased urinary bio-
marker levels predict subsequent decrease in RFR in any
population.
Both TIMP-2 and IGFBP7 have been implicated in the G1
CCA phase noted to occur during the very early stages of renal











Pre-operative (prior to protein loading) 0.8 6 0.2 0.84 6 0.2 0.9 6 0.1 0.84 6 0.2 0.2
Immediate pre-operative 0.8 6 0.2 0.83 6 0.2 0.9 6 0.2 0.83 6 0.2 0.2
Hospital discharge 0.8 (0.70.9) 0.8 (0.70.9) 0.9 (0.81.0) 0.79 (0.70.9) 0.4
3-month follow-up 0.8 (0.70.9) 0.8 (0.70.9) 1.0 (0.91.3) 0.9 (0.61.5) 0.3
eGFR (mL/min/1.73 m2)b
Pre-operative (prior to protein loading) 93.5 (84.0101.0) 94.0 (86.0101.5) 80.0 (68.087.0) 94.0 (86.0101.5) 0.2
Immediate pre-operative 93.0 (84.0101.5) 94.0 (85.5101.0) 81.0 (69.087.5) 93.5 (86.0101.0) 0.2
Hospital discharge 94.0 6 14.6 93.6 6 13.2 79.5 6 15.7 94.8 6 13.0 0.004
3-month follow-up 91.3 6 16.2 91.2 6 15.2 73.4 6 13.1 92.2 6 15.7 0.3
Resting GFR (mL/min/1.73 m2)c
Pre-operative 102.7 6 14.7 103.0 6 14.0 97.0 6 13.5 107 6 33.6 0.08
3-month follow-up 96.4 6 15.3 97.7 6 14.2 84.7 6 11.0 92.8 6 35.7 0.04
RFR (mL/min/1.73 m2)
Pre-operative 25.7 6 9.0 27.0 6 8.3 13.9 6 5.3 22.4 6 13.2 0.3
3-month follow-up 22.0 (14.927.0) 22.6 (16.928.8) 7.1 (7.411.0) 12.5 (3.6–14.8) <0.001
Preserved RFR 18 (20.9) 18 (23.7) 0 (0) 0 (0) <0.001
Reduced RFR 68 (79.1) 58 (76.3) 7 (100) 3 (100) <0.001
Urine albumin-to-creatinine ratio
Pre-operative (prior to protein loading) 5.2 (2.9–13.5) 5.0 (2.7–10.1) 30.2 (27.3–71.4) 30.0 (3.0–39.3) <0.001
Hospital discharge 10.5 (5.5–24.5) 9.1 (4.8–22.4) 21.2 (17.9–37.6) 63.4 (10.1–315.5) 0.03
3-month follow-up 7.7 (1.8–35.8) 7.4 (0.9–25.4) 30.9 (1.8–301.0) 100.8 (0.8–156.3) 0.2
Urinary [TIMP-2][IGFBP7] 0.07
0.3 (ng/mL)2/1000 within 12 h after surgery 41 (47.6) 43 (56.6) 0 (0) 0 (0)
>0.3 and <2 (ng/mL)2/1000 within 12 h after surgery 44 (51.2) 32 (42.1) 7 (100) 3 (100)
>2 (ng/mL)2/1000 within 12 h after surgery 1 (1.2) 1 (1.3) 0 (0) (0)
Values are mean 6 SD or median [25th–75th percentile (interquartile range)]. Categorical variables are expressed as n (%).
aTo convert the values for serum creatinine to lm/L, multiply by 88.4.
bThe eGFR was calculated with the CKD-Epidemiology Collaboration equation [15].
cThe resting GFR was calculated as the creatinine clearance from the urine creatinine, urine volume, collection time (in mins) and serum creatinine, and was corrected to 1.73 m2 body
surface area using the Dubois method.
Table 3. Descriptive analysis for urinary [TIMP-2][IGFBP7] at different time points depending on pre-operative and follow-up RFR
Timing of urinary [TIMP-2][IGFBP7] RFR at 3 months
<pre-operative RFR
RFR at 3 months
pre-operative RFR
P-value
30 min after initiation of cardiopulmonary bypass 0.21 (0.10–0.44) 0.08 (0.05–0.17) 0.007
ICU admission 0.06 (0.04–0.14) 0.04 (0.04–0.08) 0.15
4 h after surgery 0.11 (0.07–0.20) 0.12 (0.06–0.19) 0.81
12 h after surgery 0.11 (0.06–0.20) 0.07 (0.04–0.15) 0.051
24 h after surgery 0.11 (0.06–0.31) 0.11 (0.06–0.21) 0.46
Hospital discharge 0.46 (0.26–1.57) 0.65 (0.19–1.9) 0.93
Peak within 12 h after surgery 0.35 (0.16–0.56) 0.24 (0.19–0.38) 0.001
Peak within 24 h after surgery 0.38 (0.23–0.69) 0.32 (0.23–0.43) 0.27
3-month follow-up 0.10 (0.05–0.28) 0.06 (0.04–0.12) 0.055
Values are median [25th–75th percentile (interquartile range)].
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tubule cellular stress [12, 27]. They have been validated for the
prediction of Stages 23 AKI in different populations [12, 28, 29].
In patients undergoing cardiac surgery, [TIMP-2]•[IGFBP7]
measurements at intensive care unit (ICU) admission and 4 h after
the procedure have been described as the best time points in pre-
dicting AKI [2836]. However, these biomarkers may rise within
few minutes after kidney injury, and only one study investigated
peri-operative [TIMP-2]•[IGFBP7] levels [33]. In addition, a
faster decline of increased urinary [TIMP-2]•[IGFBP7] levels fol-
lowing cardiac surgery has been associated with higher rates of
AKI reversal at hospital discharge [30]. No study, however, has
evaluated whether increased urinary [TIMP-2]•[IGFBP7] levels
predict changes in RFR.
Study implications
Our results indicate that patients with post-operative AKI
have persistent decrease in RFR at 3 months after cardiac sur-
gery. Patients with severe AKI exhibited higher decreases in
RFR, indicating a possible direct dose-dependent relationship
between severity of cardiac surgery-associated kidney injury
and decreases in RFR. However, it remains to be determined
whether other types of AKI (e.g. in the setting of sepsis) are as-
sociated with comparable changes in RFR. Moreover, in many
patients without underlying CKD, or without clinically defined
AKI, there is a decrease of renal functional capacity after cardiac
surgery. Peri-operative elevated CCA biomarkers may be supe-
rior to help identify patients at highest risk for subsequent de-
crease of RFR after cardiac surgery compared with post-
operative time points.
Study strengths and limitations
To our knowledge, this is the first study to suggest that RFR
at 3 months after surgery may have a role in renal outcome as-
sessment after AKI and be useful for discriminating among
patients with complete functional renal recovery (normal eGFR
and intact RFR) from those with ‘apparent’ functional recovery
(normal eGFR and reduced RFR) and non-recovery (reduced
eGFR and RFR). Whether decreased RFR is a novel risk indica-
tor for new CKD remains to be determined; however, our
results suggest that a reduction of RFR may occur before CKD
becomes clinically apparent as measured by eGFR. The role of
reduced RFR in the risk of future episodes of AKI will need to
be determined. Other strengths of the study include its prospec-
tive design, simultaneous assessment of CCA biomarkers, and
assessment of multiple additional baseline variables.
Our study has several limitations including single-centre de-
sign and a relatively low AKI rate (11.6%). However, the low oc-
currence of AKI was expected since we excluded pre-existing
CKD patients. Also, we selected patients with low comorbidity
status, elective surgical procedures and a considerably high rate
of minimally invasive surgery (36%), all factors which are asso-
ciated with low AKI rates [37, 38]. Unexpectedly, none of the
AKI patients exhibited positive urine output criteria. It is well
described that urine output significantly increases in response
to protein loading [16, 23, 39]. However, whether there is a sus-
tained effect on urine output after termination of protein load-
ing—and if so, for how long—remains to be determined.
However, we did not detect any changes in serum creatinine
levels the day after protein loading as performed with red meat
FIGURE 2: Renal outcome after cardiac surgery, stratified by occurrence of AKI and biomarker levels. The figure illustrates the long-term renal
outcome in all patients stratified by the occurrence of AKI, increased biomarker levels (in the absence of clinical AKI) and without both
criteria.










FIGURE 3: Comparison of pre-operative and follow-up RFR in non-AKI verus AKI patients (A), AKI patients categorized by stage (B) and non-
AKI patients with increased urinary [TIMP-2]•[IGFBP7] levels after cardiac surgery (C). (A) At 3 months, patients with and without AKI dis-
played a significant decrease in RFR (P< 0.001). (B) When categorized by stage, patients with AKI Stage 1 and severe AKI (Stages 2–3) had a sig-
nificant decrease in RFR (P< 0.001). (C) Patients with positive biomarkers, despite not having developed AKI, had a significant decrease in RFR
(P< 0.001). In contrast, in biomarker-negative, AKI-negative patients, RFR was preserved (P¼ 0.2). A positivity of urinary [TIMP-2]•[IGFBP7]
was defined as biomarker levels >0.3 (ng/mL)2/1000. Significance between pre-operative and follow-up RFR is indicated in the figure (*P< 0.001).
Table 4. Area under the curve for urinary [TIMP-2][IGFBP7] at different time points to discriminate RFR at 3 months <pre-operative RFR in all patients
(biomarkers positive and negative)






30 min after initiation of cardiopulmonary bypass 0.72 0.06 0.59–0.85
ICU admission 0.61 0.07 0.47–0.74
4 h after surgery 0.52 0.07 0.37–0.66
12 h after surgery 0.65 0.07 0.51–0.79
24 h after surgery 0.56 0.08 0.41–0.70
Peak within 12 h after surgery 0.75 0.05 0.64–0.86
Peak within 24 h after surgery 0.72 0.06 0.60–0.84
3-month follow-up 0.65 0.07 0.51–0.79
The ROC curve of peak [TIMP-2][IGFBP7] within 12 h after cardiac surgery was the most accurate. Empirical cutpoint estimation (using the Liu Method) for peak [TIMP-2][IGFBP7] within
12 h after cardiac surgery: 0.3 (sensitivity at cutpoint: 0.68; specificity at cut-off point: 0.78; area under receiver under the operating characteristic curve at cutpoint: 0.73).
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when compared with levels at hospital admission. Follow-up
analyses of RFR were performed 3 months after cardiac surgery,
as the KDIGO guidelines [19] define 3 months as the minimum
duration to delineate new onset CKD after AKI. However, it is
likely that a longer follow-up period would have increased the
number of patients with new CKD. Different age-related nor-
mal RFR values have been described; however, whether these
values can be transferred to our cohort—and what the threshold
for a significant decrease in RFR is, needs to be determined in a
larger and heterogeneous cardiac surgery population [11, 23].
Measurement of RFR is time-consuming, which limits its wide-
spread clinical utility. Currently, no alternative methods are
available to measure RFR, but this may change with the intro-
duction of real-time GFR measurement [40]. In addition, creat-
inine clearance may overestimate RFR due to increased tubular
creatinine secretion. However, as the proportion of tubular se-
cretion to glomerular filtration of creatinine increases with ad-
vanced kidney disease, the overestimation of GFR is greater at
lower levels of kidney function, which may play only a minor
role in our population with normal renal function prior to sur-
gery. In previous studies, creatinine clearance and inulin clear-
ance for RFR measurement did not differ significantly, showing
that creatinine clearance is a reliable, easy-to-perform and avail-
able marker for GFR [11, 16, 24].
In conclusion, in patients with normal eGFR undergoing elec-
tive cardiac surgery, decreases in RFR was common. However,
clinical AKI was associated with greater changes in RFR at
3 months, and elevated peri-operative CCA biomarkers (even in
the absence of clinical AKI) also identified patients at higher risk
for subsequent decreases in RFR at 3 months. Larger prospective
studies to validate the use of RFR to assess renal recovery in com-
bination with biochemical biomarkers are warranted.
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